BioSpace News Archive

Continued transformation to a software as a service (SaaS)-based membership model with recurring revenues and higher margin profile Established partnership with Vitality Group to accelerate penetration into the self-insured employer market Expanded offering to include behavioral health coaching and full suite of telemedicine capabilities Positioned platform to potentially drive substantial revenue growth in the second half of this year Company to Host Conf

Bristol Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020. Samit Hirawat , MD, EVP, Chief Medical Officer and Chris Boerner , EVP, Chief Commercialization Officer will answer questions at 11:40 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com . Materials re

Rocket Pharmaceuticals Presents Positive Updates on FA and LAD-I Gene Therapy Programs at the 23 rd Annual Meeting of the American Society of Gene and Cell Therapy —Follow-up of 12 to 36 Months for FA RP-L102 “Process A” Demonstrates Prolonged Engraftment and Continued Hematologic Correction— —Sustained Efficacy in LAD-I Provides Initial Proof of Concept for Lentiviral Platform and “Process B” Manufacturing— —Longer-term “Process B” Data for FA a

Expands CytoSorb E.U. label that now includes the reduction of two major blood thinners, rivaroxaban (Xarelto®) and ticagrelor (Brilinta®), during on-pump cardiothoracic surgery with the goal of reducing serious perioperative bleeding complications

Industry leaders connecting patient advocacy organizations in virtual approach

Tandem Diabetes Care®, Inc. announced that it intends to offer, subject to market conditions and other factors, $250.0 million aggregate principal amount of Convertible Senior Notes due 2025 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Four Potential Vaccines in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on the Company’s Horsepox Virus Vaccine Platform Potential Vaccine, TNX-801, in Development to Protect Against Smallpox and Monkeypox Based on Horsepox Virus Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Management of Fibromyalgia; Topline Results Expected First Quarter 2021 NEW YORK, May 12, 2020 (GLOBE NEWSWIR

One of only a handful of vaccine candidates currently in human clinical trials in the world to begin initial evaluation in Canada

Announced Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039

CANTEL MEDICAL CORP. announced several business and financial updates in light of the ongoing COVID pandemic.